1,4-二氢-4-氧代-7-喹啉羧酸 | 948573-55-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1,4-二氢-4-氧代-7-喹啉羧酸
• 中文别名: 4-氧代-1,4-二氢喹啉-7-羧酸
• 英文名称: 4-oxo-1H-quinoline-7-carboxylic acid
• 英文别名: 7-carboxy-1,4-dihydroquinolin-4-one；4-Hydroxyquinoline-7-carboxylic acid
• CAS: 948573-55-5；1150618-22-6
• 化学式: C₁₀H₇NO₃
• 分子量: 189.17
• InChiKey: QNDMXIULYGYMJK-UHFFFAOYSA-N

物化性质

• 沸点：
  426.7±30.0 °C(Predicted)
• 密度：
  1.480±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为产物：
  描述：

  methyl 4-hydroxyquinoline-7-carboxylate 在 甲醇 、 lithium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 16.0h， 生成 1,4-二氢-4-氧代-7-喹啉羧酸
  参考文献：
  名称：

  WO2007/99326

  摘要：

  公开号：

文献信息

• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20200102303A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.

  化合物的结构式（I）和结构式（II），含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法，例如与疼痛、精神障碍、神经障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症）、癌症和眼部疾病相关的方法。 其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。
• QUINOLINE DERIVATIVES
  申请人：Jung Frederic Henri

  公开号：US20090076074A1

  公开（公告）日：2009-03-19

  The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 , Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

  本发明涉及公式I的喹啉衍生物或其药学上可接受的盐，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个具有在本说明书中定义的任何含义；制备它们的过程，包含它们的制药组合物以及它们在制造用于治疗细胞增殖性疾病的药物的过程中的使用。
• TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS
  申请人：Biswas Kaustav

  公开号：US20130157996A1

  公开（公告）日：2013-06-20

  Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  公式I的化合物可用作TRPM8的拮抗剂。这些化合物在治疗许多TRPM8介导的疾病和病症方面非常有用，并可用于制备用于治疗此类疾病和病症的药物和制剂。此类疾病的示例包括但不限于偏头痛和神经病性疼痛。公式I的化合物具有以下结构：其中变量的定义在此提供。
• Lipid construct for delivery of insulin to a mammal
  申请人：SDG, INC.

  公开号：US10004686B2

  公开（公告）日：2018-06-26

  The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.

  本发明涉及一种肝细胞靶向组合物，该组合物包含与脂质构建物相关联的胰岛素，脂质构建物包括两性脂质和扩展两性脂质，该构建物可靶向肝细胞显示的受体。 该组合物可包括游离胰岛素和与复合物相关的胰岛素的混合物。 可以对组合物进行修饰，以保护胰岛素和复合物不被降解。 本发明还包括制造组合物、将胰岛素装入组合物以及回收组合物中各种成分的方法。 治疗糖尿病患者的方法。
• Orally bioavailable lipid-based constructs
  申请人：SDG, INC.

  公开号：US10568835B2

  公开（公告）日：2020-02-25

  The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

  本发明体现为一种组合物，它能够通过消化道环境对通常非口服的治疗剂或诊断剂进行陪衬，从而使治疗剂或诊断剂具有生物可利用性。该组合物可以针对或不针对特定的细胞受体，如肝细胞。治疗剂包括但不限于胰岛素、降钙素、血清素和其他蛋白质。生物素或金属靶向剂可实现靶向。